JAK Inhibitor Misses Endpoint in Safety Study. Now What?
Pfizer announced results Wednesday from its FDA-mandated postmarketing safety study of tofacitinib (Xeljanz), and they don't bode well for the drug and possibly others in its class.
Compared with patients taking tumor necrosis factor (TNF) inhibitors, those assigned to tofacitinib (5
Read Article